1. Statin Use and Incidence of Parkinson's Disease in Women from the French <scp>E3N</scp> Cohort Study
- Author
-
Thi Thu Ha Nguyen, Agnès Fournier, Émeline Courtois, Fanny Artaud, Sylvie Escolano, Pascale Tubert‐Bitter, Marie‐Christine Boutron‐Ruault, Isabelle Degaey, Emmanuel Roze, Marianne Canonico, Ismaïl Ahmed, Anne C.M. Thiébaut, Alexis Elbaz, HAL UVSQ, Équipe, APPEL À PROJETS GÉNÉRIQUE 2018 - Facteurs de risque de la Maladie de Parkinson chez les femmes de la cohorte E3N - - PARKIN-WOMEN2018 - ANR-18-CE36-0006 - AAPG2018 - VALID, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Sorbonne Université (SU), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), T.T.H.N. was supported by post‐doctoral grants from the Michael J Fox foundation and the France Parkinson association. E.C. was supported by post‐doctoral grants from the Michael J Fox foundation. F.A. reports no disclosures. S.E. reports no disclosures. P.T.‐B. reports no disclosures. M.‐C.B.‐R. received speaker fees in 2020 from MAYOLI‐SPINDLER and GILEAD outside the field of the present paper. I.D. reports no disclosures. E.R. received honorarium for speech from Orkyn Aguettant, Elivie and for participating in an advisory board from Allergan and has received research support from Merz‐Pharma, Orkyn, Aguettant, Elivie, Ipsen, Allergan, Everpharma, Fondation Desmarest, AMADYS, ADCY5.org , ANR, Societé Française de Médecine Esthétique, and Dystonia Medical Research Foundation. M.C. has obtained research grant from French National Research Agency (ANR). I.A. reports no disclosures. A.C.M.T. reports no disclosures. A.E. has obtained research grants from Plan Ecophyto (French ministry of agriculture) and France Parkinson., T.T.H.N. was supported by postdoctoral grants from The Michael J. Fox Foundation and the France Parkinson Association. E.C. was supported by postdoctoral grants from The Michael J. Fox foundation. F.A., S.E., P.T.‐B., I.A., and A.C.M.T. report no disclosures. M.‐C.B.‐R. received speaker fees in 2020 from Mayoli‐Spindler and Gilead outside the field of the present article. I.D. reports no disclosures. E.R. received honorarium for speeches from Orkyn Aguettant and Elivie and for participating in an advisory board from Allergan and has received research support from Merz‐Pharma, Orkyn, Aguettant, Elivie, Ipsen, Allergan, Everpharma, Fondation Desmarest, AMADYS, ADCY5.org , French National Research Agency (ANR), Societé Française de Médecine Esthétique, and the Dystonia Medical Research Foundation. M.C. obtained a research grant from the ANR. A.E. has obtained research grants from Plan Ecophyto (French Ministry of Agriculture) and France Parkinson Association. The work reported in this article was performed during A.F.'s term as a visiting scientist at the International Agency for Research on Cancer. The authors declare no other relationships or activities that could appear to have influenced the submitted work. Relevant conflicts of interest/financial disclosures, This work was realized with data of the E3N cohort (INSERM) and supported by the Mutuelle Générale de l'Education Nationale (MGEN), Gustave Roussy Institute, and French League against Cancer for the constitution and maintenance of the cohort. This work has benefited from State aid managed by the National Research Agency (ANR) under the program 'Investment in the future' bearing the reference ANR‐10‐COHO‐0006 and under the program 'Young researcher' bearing the reference ANR‐18‐CE36‐0006‐01, as well as a subsidy from the Ministry of Higher Education, Research and Innovation for public service charges bearing the reference N°2102918823, 2103236497, and 2103586016, and from IRESP (Institut de Recherche En Santé Publique). The authors acknowledge all women enrolled in the E3N cohort for their continued participation. They are also grateful to all members of the E3N study group., This project was funded by the Michael J. Fox Foundation for Parkinson's Research and the France Parkinson Association. Funding agencies., and ANR-18-CE36-0006,PARKIN-WOMEN,Facteurs de risque de la Maladie de Parkinson chez les femmes de la cohorte E3N(2018)
- Subjects
[SDV] Life Sciences [q-bio] ,pharmacoepidemiology ,cohort studies ,drug repurposing ,Neurology ,Parkinson's disease ,[SDV]Life Sciences [q-bio] ,Neurology (clinical) ,statins - Abstract
International audience; Background: Statins represent candidates for drug repurposing in Parkinson's disease (PD). Few studies examined the role of reverse causation, statin subgroups, and dose–response relations based on time-varying exposures. Objectives: We examined whether statin use is associated with PD incidence while attempting to overcome the limitations described previously, especially reverse causation. Method: We used data from the E3N cohort study of French women (follow-up, 2004–2018). Incident PD was ascertained using multiple sources and validated by experts. New statin users were identified through linked drug claims. We set up a nested case-control study to describe trajectories of statin prescriptions and medical consultations before diagnosis. We used time-varying multivariable Cox proportional hazards regression models to examine the statins–PD association. Exposure indexes included ever use, cumulative duration/dose, and mean daily dose and were lagged by 5 years to address reverse causation. Results: The case-control study (693 cases, 13,784 controls) showed differences in case-control trajectories, with changes in the 5 years before diagnosis in cases. Of 73,925 women (aged 54–79 years), 524 developed PD and 11,552 started using statins in lagged analyses. Ever use of any statin was not associated with PD (hazard ratio [HR] = 0.87, 95% confidence interval [CI] = 0.67–1.11). Alternatively, ever use of lipophilic statins was significantly associated with lower PD incidence (HR = 0.70, 95% CI = 0.51–0.98), with a dose–response relation for the mean daily dose (P-linear trend = 0.02). There was no association for hydrophilic statins. Conclusion: Use of lipophilic statins at least 5 years earlier was associated with reduced PD incidence in women, with a dose–response relation for the mean daily dose. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society
- Published
- 2023